SPRY Projected Dividend Yield
ARS Pharmaceuticals Inc ( NASDAQ : SPRY )ARS Pharmaceuticals is a biopharmaceutical company focused on utilizing its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. Co. has engineered SBT8230 to treat chronic hepatitis B virus by eliciting an anti-viral immune response through targeting TLR8 activation to the liver. SBT8230 is comprised of an ASGR1 monoclonal antibody conjugated to the same TLR8 linker-payload as SBT6050, but with an average drug antibody ratio (DAR) of about two as opposed to the average DAR of about four used in SBT6050. 20 YEAR PERFORMANCE RESULTS |
SPRY Dividend History Detail SPRY Dividend News SPRY Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |